Positron emission tomography (PET) with ligands targeting the prostate-specific membrane antigen (PSMA) is being increasingly utilized, with applications including treatment planning in patients with metastatic prostate cancer (PC) [1, 2]. This evidence concerns the gene FOLH1 and pachyonychia congenita.